Compare YieldMax MSTR Option Income Strategy ETF (MSTY) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax MSTR Option Income Strategy ETF vs Tango Therapeutics Inc. — how do they compare? YieldMax MSTR Option Income Strategy ETF trades at $14.26 (market cap $1.14B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Tango Therapeutics Inc. is far larger — about 3.3× YieldMax MSTR Option Income Strategy ETF's market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, YieldMax MSTR Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax MSTR Option Income Strategy ETF for 31 Days and Tango Therapeutics Inc. for 0 Days on average.
| MSTY | TNGX | |
|---|---|---|
Market Cap | $1.14B | $3.75B |
Volume | 1,611,783 | 9,619,106 |
Sector | Income / Options Overlay | Health |
52-Week High | $63.60 | $32.90 |
52-Week Low | $11.55 | $7.50 |
Typical Hold Time | 31 Days | 0 Days |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTY trades at $15.52, down 0.13% on the day, with a bearish technical outlook as moving averages signal selling pressure. The ETF's high distribution rate, exceeding 100% annualized, is a key feature but has coincided with significant NAV erosion, as noted in recent financial media. Recent weekly dividend announcements from YieldMax highlight the income focus, but underlying asset volatility remains a concern.
The outlook is cautious; while the high yield is attractive for income-seeking investors, it comes with substantial risk of principal depletion. Analyst sentiment is mixed, balancing the tactical income opportunity against structural concerns about the fund's long-term sustainability in volatile markets.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About YieldMax MSTR Option Income Strategy ETF
MSTY is an actively managed ETF that pursues a synthetic covered call strategy on MicroStrategy Incorporated (MSTR) stock. The fund primarily sells call options on MSTR and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the volatile, Bitcoin-correlated growth potential of MSTR while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on MSTY →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
